PEG IFN VS INTRON A FOR CHRONIC IFN NAIVE HEPATITIS C

PEG IFN 与内含子 A 治疗慢性 IFN 幼稚丙型肝炎

• 批准号: 6118137
• 负责人: John G. McHutchison
• 金额: $ 2.74万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6118137
• 关键词: clinical research; drug screening /evaluation; hepatitis C; human subject; human therapy evaluation; immunotherapy; interferon alpha; liver disorder chemotherapy; polyethylene glycols

This study addresses the efficacy and safety of PEG-IFN compared to Intron A. The biochemical and virological response to treatment are measured at two time points: at the end of treatment and six months posttreatment sustained response. Secondary endpoints iclude improvement in liver biopsy at posttreatment (based on the sum of Knodell scores I+II+III), time to response, and time to relapse.

本研究探讨了PEG-IFN与内含子a相比的有效性和安全性。在两个时间点测量了对治疗的生化和病毒学反应：治疗结束时和治疗后6个月的持续反应。次要终点包括治疗后肝活检的改善（基于Knodell评分I+II+III的总和）、缓解时间和复发时间。